| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 37.59 | 54.9% | 98.6% |
| Total Income | 37.59 | 54.9% | 98.6% |
| Expenditure | 24.80 | 13.5% | 21.6% |
| PBT | 11.72 | 646.5% | 565.1% |
| Net Profit | 11.58 | 647.1% | 547.1% |
| OPM | 34.04% | 24.09pp | 41.83pp |
| NPM | 30.80% | 24.40pp | 44.46pp |
| EPS | 0.42 | 600.0% | 520.0% |
Eton Pharmaceuticals Reports Q2 2026 Financial Results with Record Revenue and Guidance Raise
14 Aug 2026 · 14 Aug, 1:49 am
Summary
Eton Pharmaceuticals announced outstanding financial results for the second quarter of 2026, driven by a 99% year-over-year revenue growth to $37.6 million. The company reported GAAP EPS of $0.35 and non-GAAP EPS of $0.43, with Adjusted EBITDA at $16.2 million. Management has raised the full-year revenue guidance to exceed $145 million and expects an Adjusted EBITDA margin of at least 35%, reflecting strong performance and strategic business developments including product relaunches and acquisitions.
Key Highlights
- 1
Eton Pharmaceuticals reported record revenue for Q2 2026, with product sales reaching $37.6 million, marking a 99% growth over the prior year period.
- 2
The company reported Q2 2026 fully diluted GAAP EPS of $0.35 and non-GAAP fully diluted EPS of $0.43.
- 3
EBITDA for Q2 2026 was $14.1 million, with Adjusted EBITDA at $16.2 million.
- 4
Full year 2026 revenue guidance has been raised to exceed $145 million, up from previous guidance of more than $120 million.
- 5
The HEMANGEOL® product was successfully relaunched on May 1st, with patient conversion completed ahead of schedule.
- 6
Eton acquired the late-stage product candidate ASN-001, expanding its infantile hemangioma franchise and anticipating a potential 2027 NDA submission.
- 7
A Prior Approval Supplement was submitted to the FDA for KHINDIVI® to expand its indication, targeting potential H1 2027 approval.
Management Comments
Sean Brynjelsen
Eton reported another outstanding quarter, delivering 99% year-over-year revenue growth, reflecting the strength of our rare disease portfolio and the exceptional execution of our team. Our HEMANGEOL relaunch is off to a strong start, with the patient conversion completed ahead of schedule, positioning our therapy for continued momentum and furthering our mission to allow more infants with infantile hemangiomas to benefit from timely treatment. In addition, we further expanded our commitment to the infantile hemangioma community with the licensing of ASN-001, an exciting late-stage development program that is expected to further improve care and broaden treatment options for families, while potentially becoming the largest revenue opportunity in our pipeline. The rest of our portfolio continued to deliver in the quarter, with strong contributions from our entire pediatric endocrinology franchise, including the recently launched DESMODA™, and our metabolic products. Given our first half performance and strong outlook for the remainder of the year, we’re pleased to again raise our annual revenue guidance and now expect at least $145 million of revenue this year. We are also raising our adjusted EBITDA guidance, which includes the additional expenses related to the ASN-001 transaction and development. We now expect to deliver an Adjusted EBITDA margin of at least 35%.
Informational and educational content only. Not investment advice.